Abstract:Human CYP1B1 as one member in CYP1 family could catalyze the bioactivation of certain procarcinogens.It plays a pivotal role in the carcinogenic action of 17-β-estradiol.Recent knowledge relating to the high and consistent expression of this enzyme in various tumor organs and the involvement of it in anti-cancer drug resistance,make the inhibition of CYP1B1 as a new method in cancer prevention and therapy.Resveratrol,an inhibitor of CYP1B1,has been deemed as one of the potential chemopreventive trans-stilbenes.α-Naphthoflavone(ANF)as a strong and selective inhibitor of CYP1B1,has been employed for eliminating CYP1B1-mediated anti-cancer drug resistance in vitro.Taking ANF as a lead,α-(E)-styryl-4,5,8-trimethoxy naphthalene(Ⅰ1)and its derivatives(Ⅰ2-Ⅰ10)as the structural analogues of the lead were synthesized via the Horner-Wadsworth-Emmons reactions between phosphonates and 4,5,8-trimethoxy-1-naphthaldehyde.β-(E)-Styryl-1,4,8-trimethoxy naphthalenes(Ⅱ1-Ⅱ8)and β-(E)-styryl-1,4,5,8-tetramethoxy naphthalenes(Ⅲ1-Ⅲ8)were also prepared to examine the influence of the position of the styryl moiety on the naphthalene part of these new compounds towards CYP1B1 inhibition.All the candidates prepared were evaluated for their inhibitory effects on CYP1B1-mediated EROD activity.The results suggested that most of these new compounds were more potent inhibitors of human CYP1B1 enzyme than resveratrol.Compared with the lead,compounds Ⅰ2,Ⅰ8,Ⅲ2,Ⅲ4 exhibited much higher potency and selectivity towards CYP1B1 inhibition.The SARs analysis indicated that α-(E)-styryl-4,5,8-trimethoxy naphthalenes(Ⅰ)were stronger inhibitors than the corresponding β-(E)-styryl-1,4,8-trimethoxy naphthalenenes(Ⅱ)and β-(E)-styryl-1,4,5,8-tetramethoxy naphthalenes(Ⅲ).The introduction of 3′,4′,5′-OMe groups or a 4′-OMe substitution on the styryl moiety of Ⅰ,Ⅱ and Ⅲ,caused sharp decrease in their inhibitory effects.On the contrary,the derivatives with the 2′-OMe substitution(Ⅰ8,Ⅱ6,Ⅲ6)exhibited increased inhibitory potency.Meanwhile,4′-F analogues(Ⅰ2,Ⅱ2,Ⅲ2)showed more potent inhibition than the corresponding 4′-Cl and 4′-OMe analogues.Among the tested ones,Ⅰ2 exhibited the strongest inhibition effects with the IC50 value of 0.31 nmol · L-1.

Perspective Of Structural Flexibility On Selective Inhibition Towards Cyp1b1 Over Cyp1a1 By Alpha-Naphthoflavone Analogs

Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs

Synthesis and Structure-Activity Relationship Studies of Α-Naphthoflavone Derivatives As CYP1B1 Inhibitors.

Design and synthesis of new alfa-naphthoflavanones as potent and selective CYP1B1 inhibitors

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Flavonoids and Naphthoflavonoids: Wider Roles in the Modulation of Cytochrome P450 Family 1 Enzymes.

Discovery of Heterocycle-Containing Α-Naphthoflavone Derivatives As Water-Soluble, Highly Potent and Selective CYP1B1 Inhibitors.

Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors

α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship

Synthesis of styrylnaphthalenes as potent inhibitors of CYP1B1

Design and Synthesis of New Α-Naphthoflavones As Cytochrome P450 (CYP) 1B1 Inhibitors to Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression

Design and Synthesis of New 7,8-Dimethoxy-α-naphthoflavones As CYP1A1 Inhibitors

Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors

Inhibitors and Prodrugs Targeting Cyp1: A Novel Approach in Cancer Prevention and Therapy

Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation

CYP1A inhibitors: Recent progress, current challenges, and future perspectives

Investigation of binding features: effects on the interaction between CYP2A6 and inhibitors.

Design, Synthesis and Biological Evaluation of Highly Potent and Selective CYP1B1 Inhibitors

Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1

Recent Research Progress on the CYP1B1 Inhibitors

Structure, Chemistry and Pharmacology of Naphthoflavones